Connect Sign In
Days before the public comment period ends, ARUP Laboratories’ experts host webinar to educate and encourage attendees to provide comments on the FDA’s proposed rule to regulate lab-developed tests.
ARUP believes the FDA’s plan to regulate lab-developed tests will limit access to testing, increase costs, and face a court challenge, and is calling for collaboration to better address LDT oversight.
ARUP experts seek to increase understanding of the FDA’s proposed rule to regulate lab-developed tests as medical devices and the impact on hospitals and patients during a webinar on November 29.
ARUP has gained a Conformité Européenne (CE) mark for AAV5 DetectCDx™ single-site use. The test will aid in determining the eligibility of non-U.S. patients for a new hemophilia A gene therapy.
During a networking event cohosted by ARUP, leaders in the life sciences advocated for more returnships to help those who have taken time off ease back into careers in STEM.
ARUP Blood Services has announced the rollout of its Whole Blood Titan program, which will encourage donations of low-titer, type O blood that is vital to saving lives in emergency situations.
A platform clients use to reduce testing waste, lower cost per test, and improve patient safety has won the prestigious Choosing Wisely Champion Award from the American Society for Clinical Pathology.
The FDA’s newly proposed rules would regulate all in vitro diagnostic products as medical devices if enacted. ARUP believes additional FDA oversight would disrupt the diagnostic testing market.
New ARUP Institute for Research and Innovation in Diagnostic and Precision Medicine™ will improve patient lives by advancing groundbreaking diagnostic and prognostic technologies.
Forbes magazine has listed ARUP as one of the 2023 Best Employers by State based on employer recommendations from employees and others in Utah in a recent survey conducted by Statista.
